Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Cited by (1,000)

Items 401–500 of 1,000

1. Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors
   Jennifer L. Macdonald-Obermann, LINDA JOY PIKE · 2018 · Journal of Biological Chemistry
2. Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
   Feng Wang, Xuewen Liu, Boris Bartholdy, Haiying Cheng, Balázs Halmos · 2019 · Translational Cancer Research
3. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism
   Lingaku Lee, Irene Ramos-Álvarez, Terry W. Moody, Samuel A. Mantey, Robert T. Jensen · 2019 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
4. Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients
   Keatdamrong Janpipatkul, Narumol Trachu, Piyakarn Watcharenwong, Wittaya Panvongsa, Wittawin Worakitchanon, Chanatip Metheetrairut, Songporn Oranratnachai, Thanyanan Reungwetwattana, Arthit Chairoungdua · 2021 · Cancer Biomarkers
5. Targeting Receptor Tyrosine Kinases in Cancer
   Wolfgang J. Köstler, Christoph Carl Zielinski · 2014 · Springer eBooks
6. A High-Content Biosensor-Based Screen Identifies Cell-Permeable Activators and Inhibitors of EGFR Function: Implications in Drug Discovery
   Christophe Antczak, Jeni P. Mahida, Bhavneet Bhinder, Paul A. Calder, Hakim Djaballah · 2012 · SLAS DISCOVERY
7. Erlotinib: early clinical development in brain cancer
   Raffaele Addeo, Silvia Zappavigna, Ciro Parlato, Michele Caraglia · 2014 · Expert Opinion on Investigational Drugs
8. Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors
   Yoshimi Ohashi, Mutsumi Okamura, Ryohei Katayama, Siyang Fang, Saki Tsutsui, Akinobu Akatsuka, Mingde Shan, Hyeong-Wook Choi, Naoya Fujita, Kentaro Yoshimatsu et al. · 2017 · Oncotarget
9. Concise Review: Cancer Cells Escape from Oncogene Addiction: Understanding the Mechanisms Behind Treatment Failure for More Effective Targeting
   Francesca Pellicano, Leena Mukherjee, Tessa L. Holyoake · 2014 · Stem Cells
10. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer
    Meng Wang, Jing Zhao, Lian min Zhang, Hui Li, Jin-Pu Yu, Xiu-Bao Ren, Chang-Li Wang · 2012 · Journal of Cancer Research and Clinical Oncology
11. Domain-Based Biosensor Assay to Screen for Epidermal Growth Factor Receptor Modulators in Live Cells
    Christophe Antczak, Alun Bermingham, Paul Calder, Dmitry Malkov, Keming Song, John R. Fetter, Hakim Djaballah · 2012 · Assay and Drug Development Technologies
12. Role of Genotyping in Non-Small Cell Lung Cancer Treatment
    Laura Bonanno, Adolfo Gino Favaretto, Massimo Rugge, Miquel Tarón, Rafael Rosell · 2011 · Drugs
13. Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition.
    Ming Liu, Chenzhi Zhou, Jian Zheng · 2015 · Europe PMC (PubMed Central)
14. HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells
    Zhihao Wang, Pengchao Hu, Fang Tang, Conghua Xie · 2016 · Medical Oncology
15. Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
    Takahiro Yoshizawa, Ken Uchibori, Mitsugu Araki, Shigeyuki Matsumoto, Biao Ma, Ryo Kanada, Yosuke Seto, Tomoko Oh‐hara, Sumie Koike, Ryo Ariyasu et al. · 2021 · npj Precision Oncology
16. STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway
    Hui Xu, Xiaomei Yang, Xiaofeng Xuan, Di Wu, Jieru Zhang, Xinchun Xu, Yuanjie Zhao, Chunping Ma, Dawei Li · 2021 · Neoplasia
17. Biosocial medicine: Biology, biography, and the tailored care of the patient
    Ralph I. Horwitz, Gabriella R. Lobitz, McKayla Mawn, Allison Hayes Conroy, Mark R. Cullen, Ida Sim, Burton H. Singer · 2021 · SSM - Population Health
18. Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
    Gulam Mustafa Hasan, Md. Imtaiyaz Hassan, Sukhwinder Singh Sohal, Anas Shamsi, Manzar Alam · 2023 · ACS Omega
19. A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen
    Boryana M. Eastman, Minji Jo, Drue L. Webb, Shinako Takimoto, Steven L. Gonias · 2012 · Cellular Signalling
20. NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC
    Cindy Mendes, Isabel Lemos, Inês Francisco, Teresa Almodôvar, Fernando Q. Cunha, Cristina M Albuquerque, Luís G. Gonçalves, Jacinta Serpa · 2023 · Lung Cancer
21. Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction
    Qing Xu, Mao Mao, Guangjuan Zheng, Yazhen Zhu, Xirun Zheng, Yali Bai, Xiumin Wei · 2015 · OncoTargets and Therapy
22. MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer
    Shuiliang Wang, Ling Zhu, Weimin Zuo, Zhiyong Zeng, Lianghu Huang, Fengjin Lin, Rong Lin, Jin Wang, Jun Lü, Qinghua Wang et al. · 2016 · Oncotarget
23. Chitooligosaccharides-modified PLGA nanoparticles enhance the antitumor efficacy of AZD9291 (Osimertinib) by promoting apoptosis
    Xiaochao Hu, Shumin Chen, Hao Yin, Qi Wang, Yourong Duan, Lihua Jiang, Liming Zhao · 2020 · International Journal of Biological Macromolecules
24. Targeting Notch and EGFR signaling in human mucoepidermoid carcinoma
    Wei Min NI, Zirong Chen, Xin Zhou, Rongqiang Yang, Mu Yu, Jianrong Lu, Frederic J. Kaye, Lizi Wu · 2021 · Signal Transduction and Targeted Therapy
25. Database and tools for metabolic network analysis
    Lu Shi Jing, Farah Fathiah Muzaffar Shah, Mohd Saberi Mohamad, Nur Laily Hamran, Abdul Hakim Mohamed Salleh, Safaai Deris, Hany Alashwal · 2014 · Biotechnology and Bioprocess Engineering
26. Dsh Homolog DVL3 Mediates Resistance to IGFIR Inhibition by Regulating IGF-RAS Signaling
    Shan Gao, Ilirjana Bajrami, Clare L. Verrill, Asha Kigozi, Djamila Ouaret, Tamara Aleksic, Ruth G. Asher, Cheng Han, Paul W. Allen, Deborah Bailey et al. · 2014 · Cancer Research
27. Asialoglycoprotein Receptor Promotes Cancer Metastasis by Activating the EGFR–ERK Pathway
    Suguru Ueno, Marija Mojić, Yoshimi Ohashi, Nobuaki Higashi, Yoshihiro Hayakawa, Tatsuro Irimura · 2011 · Cancer Research
28. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research
    Maria Bonomi, Sara Pilotto, Michèle Milella, Francesco Massari, Sara Cingarlini, Matteo Brunelli, Marco Chilosi, Giampaolo Tortora, Emilio Bria · 2011 · Journal of Experimental & Clinical Cancer Research
29. Genomic Alteration During Metastasis of Lung Adenocarcinoma
    Qiang Tan, Jian Cui, Jia Ming Huang, Zhengping Ding, Hao Lin, Xiaomin Niu, Zhiming Li, Guan Wang, Qingquan Luo, Shun Lu · 2016 · Cellular Physiology and Biochemistry
30. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer
    Richeng Jiang, Xinyue Wang, Kai Li · 2016 · Oncotarget
31. B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers
    Wen‐Cheng Chou, Weiting Chen, Chia‐Ni Hsiung, Ling‐Yueh Hu, Jyh‐Cherng Yu, Huan-Ming Hsu, Chen‐Yang Shen · 2017 · Scientific Reports
32. Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation
    Ichidai Tanaka, Masahiro Morise, Ayako Miyazawa, Yuta Kodama, Yutaro Tamiya, Soei Gen, Akira Matsui, Tetsunari Hase, Naozumi Hashimoto, Mitsuo Sato et al. · 2020 · Clinical Lung Cancer
33. EphrinA5 suppresses colon cancer development by negatively regulating epidermal growth factor receptor stability
    Tong‐Hong Wang, Junn‐Liang Chang, Jar‐Yi Ho, Hsiao‐Chun Wu, Tse‐Ching Chen · 2011 · FEBS Journal
34. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
    Kaiwen Wang, Robyn R. Du, Nathaniel James Myall, Whitney E. Lewis, Natalie F. Uy, Lingzhi Hong, Ferdinandos Skoulidis, Lauren A. Byers, Anne S. Tsao, Tina Cascone et al. · 2023 · Journal of Thoracic Oncology
35. Revolutionizing lung cancer treatment: Nanotechnology-driven advances in targeted drug delivery and novel therapeutic strategies
    Shirin Shojaei, Mehrab Pourmadadi, Mina Homayoonfal, Parisa Behnamrad, Sonia Fathi‐karkan, Abbas Rahdar, Sina Gerayli, Sadanand Pandey · 2024 · Journal of Drug Delivery Science and Technology
36. Innovative design and potential applications of covalent strategy in drug discovery
    Tianyong Tang, Jiaxiang Luo, Dan Zhang, Yang Lü, Wen Liao, Jifa Zhang · 2024 · European Journal of Medicinal Chemistry
37. Rare Mutations in Non-Small-Cell Lung Cancer
    Manolo D’Arcangelo, Armida D’Incecco, Federico Cappuzzo · 2013 · Future Oncology
38. Strengthening Context-Dependent Anticancer Effects on Non–Small Cell Lung Carcinoma by Inhibition of Both MET and EGFR
    Yu-Wen Zhang, Ben Staal, Curt J. Essenburg, Steven Lewis, Dafna W. Kaufman, George F. Vande Woude · 2013 · Molecular Cancer Therapeutics
39. Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial–mesenchymal transition phenotype
    Yuji Sakuma, Hirotaka Nishikiori, Sachie Hirai, Miki Yamaguchi, Gen Yamada, Atsushi Watanabe, Tadashi Hasegawa, Takashi Kojima, Toshiro Niki, Hiroki Takahashi · 2016 · Laboratory Investigation
40. Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers
    Veronica L. Cox, Priya Bhosale, Gauri Rajani Varadhachary, Nicolaus A. Wagner‐Bartak, Isabella C. Glitza, Kathryn Ann Gold, Johnique T. Atkins, Pamela T. Soliman, David S. Hong, Aliya Qayyum · 2017 · Radiology
41. Landscape of drug-resistance mutations in kinase regulatory hotspots
    Pora Kim, Hanyang Li, Junmei Wang, Zhongming Zhao · 2020 · Briefings in Bioinformatics
42. Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer
    Wanheng Zhang, Kuojun Zhang, Yiwu Yao, Yunyao Liu, Yong Ni, Chenzhong Liao, Zhengchao Tu, Yatao Qiu, Dexiang Wang, Dong Chen et al. · 2020 · European Journal of Medicinal Chemistry
43. Quinazolinone-based hybrids with diverse biological activities
    Rezvan Rezaeinasab, Elham Jafari, Ghadamali Khodarahmi · 2022 · Journal of Research in Medical Sciences
44. Molecular pathology of non‐small cell carcinoma
    Yasushi Yatabe · 2023 · Histopathology
45. The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion
    Emily Cheng, Timothy G. Whitsett, Nhan L. Tran, Jeffrey A. Winkles · 2014 · Molecular Cancer Research
46. Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3′-Deoxy-3′-[18F]-Fluorothymidine Positron Emission Tomography
    Francesca Iommelli, Viviana De Rosa, Sara Gargiulo, Mariarosaria Panico, Marcello Monti, Adelaide Greco, Matteo Gramanzini, Giovanni Ortosecco, Rosa Fonti, Arturo Brunetti et al. · 2014 · Clinical Cancer Research
47. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations
    Tadaaki Yamada, Shinji Takeuchi, Naoya Fujita, Akito Nakamura, Wei Wang, Q Li, M. Oda, Tetsuya Mitsudomi, Yasushi Yatabe, Yoshitaka Sekido et al. · 2012 · Oncogene
48. Evolutionary karyotypic theory of cancer versus conventional cancer gene mutation theory
    Aleksei A. Stepanenko, VADIM M. KAVSAN · 2012 · Biopolymers and Cell
49. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer
    Fayong Hu, Xiaonian Cao, Qinzi Xu, Yu Deng, Senyan Lai, Jing Ma, Junbo Hu · 2016 · Journal of Huazhong University of Science and Technology [Medical Sciences]
50. Allosteric Inhibitor TREA‐0236 Containing Non‐hydrolysable Quinazoline‐4‐one for EGFR T790M/C797S Mutants Inhibition
    Seoyoung Lee, Jiwon Kim, Krishna Babu Duggirala, Areum Go, Inji Shin, Byoung Chul Cho, Gildon Choi, Chong Hak Chae, Kwangho Lee · 2018 · Bulletin of the Korean Chemical Society
51. C-X-C chemokine receptor 2 correlates with unfavorable prognosis and facilitates malignant cell activities via activating JAK2/STAT3 pathway in non-small cell lung cancer
    Lin Wei, Yugang Liu, Yuefeng Ma, Chao Ding, Huijun Zhang, Zhenghui Lu, Zhenning Gu, Changsheng Zhu · 2019 · Cell Cycle
52. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
    Rossana Berardi, Matteo Santoni, Francesca Morgese, Ballatore, Savini, Onofri, Mazzanti, Mirco Pistelli, Riccardo Pierantoni, De Lisa et al. · 2013 · OncoTargets and Therapy
53. Lazertinib: breaking the mold of third-generation EGFR inhibitors
    Kishan B. Patel, David E. Heppner · 2025 · RSC Medicinal Chemistry
54. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy
    Jihye Kim, Vihas T. Vasu, Rangnath Mishra, Katherine R. Singleton, Minjae Yoo, Sonia M. Leach, Eveline Farias‐Hesson, Robert J. Mason, Jaewoo Kang, Preveen Ramamoorthy et al. · 2014 · Bioinformatics
55. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
    Dario Presutti, Simonetta Santini, Beatrice Cardinali, Giuliana Papoff, Cristiana Lalli, Simone Samperna, Valentina Fustaino, Giuseppe Giannini, Giovina Ruberti · 2015 · PLoS ONE
56. Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies
    Sheng Jin, Ya-Xiong Zhang, Xiao-Bo He, Wenfeng Fang, Yun-Peng Yang, Gui‐Nan Lin, Xuan Wu, Ning Li, Jing Zhang, Lin-Zhu Zhai et al. · 2016 · The Oncologist
57. Clinical applications of liquid biopsies for early lung cancer detection.
    Hao Zheng, Xinyu Wu, Jie Yin, Shuang Wang, Zhi Li, Changxuan You · 2019 · PubMed Central
58. Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
    Christopher D. Delaney, Samuel Frank, R. Stephanie Huang · 2015 · 癌症：英文版
59. Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics
    J. Clay Callison, Ronald C. Walker, Pierre P. Massion · 2011 · Journal of Lung Cancer
60. New targeted therapies for gastric cancer
    Yoshinari Asaoka, Tsuneo Ikenoue, Kazuhiko Koike · 2011 · Expert Opinion on Investigational Drugs
61. Activated platelets rescue apoptotic cells via paracrine activation of EGFR and DNA-dependent protein kinase
    Amanda E. Au, Maithili Sashindranath, Rachael J. Borg, O Kleifeld, Robert K. Andrews, Elizabeth E. Gardiner, Robert Lindsay Medcalf, André L. Samson · 2014 · Cell Death and Disease
62. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Hidetaka Uramoto, Tadaaki Yamada, Seiji Yano, Nobuyuki Kondo, Seiki Hasegawa, Fumihiro Tanaka · 2012 · PubMed
63. Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors
    Jin Han, Silje Henriksen, Kristin G. Nørsett, Eirik Sundby, Bård Helge Hoff · 2016 · European Journal of Medicinal Chemistry
64. Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway
    Seungwoo Hong, Nam-Sook Park, Min Hye Noh, Ju A Shim, Byul‐Nim Ahn, Yeong Seok Kim, Daejin Kim, Hyun-Kyung Lee, Dae Young Hur · 2017 · Lung Cancer
65. Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
    Chen Hu, Aoli Wang, Hong Wu, Ziping Qi, Xixiang Li, Xiao-E Yan, Chen Cheng, Kailin Yu, Fengming Zou, Wenchao Wang et al. · 2017 · Oncotarget
66. Identification of Small-Molecule EGFR Allosteric Inhibitors by High-Throughput Docking
    Fabiana Caporuscio, Annachiara Tinivella, Valentina Restelli, Marta Stefania Semrau, Luca Pinzi, Paola Storici, Massimo Broggini, Giulio Rastelli · 2018 · Future Medicinal Chemistry
67. Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy
    Göknur Kara, Ayhan Parlar, Melike Çokol Çakmak, Murat Cokol, Emir Baki Denkbaş, Feray Bakan · 2020 · Colloids and Surfaces B Biointerfaces
68. The human condition: an immunological perspective
    Ronald N. Germain, Pamela L. Schwartzberg · 2011 · Nature Immunology
69. Synthesis of novel [1,2,3]triazolo[4′,5′:3,4]pyrrolo[1,2‐a]thieno[2,3‐d] pyrimidines: Potent EGFR targeting anti‐breast cancer agents
    Rajkumar Samala, Ranadheer Kumar M, Ashok Kumar Bapuram, Venkatarathnam Nasipireddy, Sirassu Narsimha · 2024 · Journal of Heterocyclic Chemistry
70. JMJD6 K375 acetylation restrains lung cancer progression by enhancing METTL14/m6A/SLC3A2 axis mediated cell ferroptosis
    Huanxiang Chen, Nan Xiao, Chenxing Zhang, Yang Li, Xiangzhuan Zhao, Ruike Zhang, Lu Bai, Qiaozhen Kang, Junhu Wan, Hongyang Liu · 2025 · Journal of Translational Medicine
71. A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC
    Minji Lim, Juhee Park, Alarice Cheng-Yi Lowe, Hyoung‐oh Jeong, Semin Lee, Hee Chul Park, Kyusang Lee, Gwang Ha Kim, Mi Hyun Kim, Yoon‐Kyoung Cho · 2020 · Theranostics
72. Inhibition of autophagy by YC-1 promotes gefitinib induced apoptosis by targeting FOXO1 in gefitinib-resistant NSCLC cells
    Hui Hu, Xiaowei Zhang, Li Lin, Ming-Ning Hu, Wen-Qian Hu, Jingying Zhang, Xiaokang Miao, Wenle Yang, Lingyun Mou · 2021 · European Journal of Pharmacology
73. Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers
    Lu Liu, Wěi Li, Le Yang, Zitao Guo, Hao Xue, Ningjie Xie, Xiaoyan Chen · 2021 · Acta Pharmacologica Sinica
74. Polysaccharides from marine resources exhibit great potential in the treatment of tumor: A review
    Hao Ju, Chong Ho Alex Yu, Wei Liu, Hai‐Huang Li, Ze Qiang Fu, Yan‐Chao Wu, Pi‐Xian Gong, Hui-Jing Li · 2023 · Carbohydrate Polymer Technologies and Applications
75. Pharmacogenomics: will the promise be fulfilled?
    Russ Biagio Altman, Heyo K. Kroemer, Catherine Anne McCarty, Mark J. Ratain, Dan M. Roden · 2010 · Nature Reviews Genetics
76. Diacylglycerol Kinase δ Modulates Akt Phosphorylation through Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatase 2 (PHLPP2)
    Tracy M. Crotty, Tomoyuki Nakano, Diana M. Stafforini, Matthew K. Topham · 2012 · Journal of Biological Chemistry
77. LIN-3/EGF Promotes the Programmed Cell Death of Specific Cells in Caenorhabditis elegans by Transcriptional Activation of the Pro-apoptotic Gene egl-1
    Hang-Shiang Jiang, Yi‐Chun Wu · 2014 · PLoS Genetics
78. Combined Treatment withEpimedium koreanumNakai Extract and Gefitinib Overcomes Drug Resistance Caused by T790M Mutation in Non-Small Cell Lung Cancer Cells
    Jie Song, Rongling Zhong, Houcai Huang, Zhenhai Zhang, Dongmei Ding, Hongmei Yan, E Sun, Xiao‐Bin Jia · 2014 · Nutrition and Cancer
79. Quantitative and Simplified Analysis of 11C-Erlotinib Studies
    Maqsood M. Yaqub, Idris Bahce, Charlotte Voorhoeve, Robert C. Schuit, Albert D. Windhorst, Otto S. Hoekstra, Ronald Boellaard, N. Harry Hendrikse, Egbert Frederik Smit, Adriaan A. Lammertsma · 2016 · Journal of Nuclear Medicine
80. Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment
    S Ghione, Nesrine Mabrouk, Catherine Paul, Ali Bettaı̈eb, Stéphanie Plenchette · 2020 · Biochemical Pharmacology
81. Identification of Transcriptional Subgroups in EGFR -Mutated and EGFR / KRAS Wild-Type Lung Adenocarcinoma Reveals Gene Signatures Associated with Patient Outcome
    Maria Planck, Sofi Isaksson, Srinivas Veerla, Johan Staaf · 2013 · Clinical Cancer Research
82. Targeted Lipid-Based Drug Delivery Systems for Lung Cancer Therapy
    Maria Apostolou, Amos A. Fatokun, Sulaf A. Assi, Iftikhar Khan · 2024 · Applied Sciences
83. The Current State of Molecularly Targeted Drugs Targeting HGF/Met
    Seiji Yano, T. Nakagawa · 2013 · Japanese Journal of Clinical Oncology
84. Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts
    Qingyu Stephanie Zhou, Xiaofang Guo, Riya Choksi · 2017 · Journal of Pharmacology and Experimental Therapeutics
85. FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma
    Zhi Shang, Xiaomin Niu, Kewei Zhang, Zhi Qiao, Sha Liu, Xiaoteng Jiang, Chengxi Cao, Shun Lü, Hua Xiao · 2019 · Journal of Molecular Medicine
86. Extensive functional evaluation of exon 20 insertion mutations of EGFR
    Takeshi Hirose, Masachika Ikegami, Makoto Endo, Yoshihiro Matsumoto, Yasuharu Nakashima, Hiroyuki Mano, Shinji Kohsaka · 2020 · Lung Cancer
87. Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation
    Awwad A. Radwan, Fars K. Alanazi, Abdullah Al‐Dhfyan · 2024 · PLoS ONE
88. Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: new strategy against cancer
    Ronan Shaughnessy, Cláudio Retamal, Claudia Oyanadel, Andrés Norambuena, Alejandro López, Marcela Bravo‐Zehnder, Fabián Montecino, Claudia Metz, Andrea Soza, Alfonso González · 2014 · FEBS Journal
89. New Approaches to Targeted Therapy in Lung Cancer
    William J. Pao · 2012 · Proceedings of the American Thoracic Society
90. Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis
    Giulia Maria Stella, Simona Inghilleri, Ymera Pignochino, Michele Zorzetto, Tiberio Oggionni, Patrizia Morbini, Maurizio Luisetti · 2014 · Translational Oncology
91. Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy
    Caixia Lian, Ling‐Ling Ruan, Dongsheng Shang, Yanfang Wu, Yongjin Lu, Peng Lü, Yuhua Yang, Yajun Wei, XiaoJing Dong, Dewan Ren et al. · 2016 · Cancer Biotherapy and Radiopharmaceuticals
92. Discovery of novel small molecule EGFR inhibitory leads by structure and ligand-based virtual screening
    Priya Mahajan, Nitasha Suri, Rukmankesh Mehra, Monika Gupta, Amit Kumar, Shashank Kumar Singh, Amit Nargotra · 2016 · Medicinal Chemistry Research
93. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer
    Moulid Hidayat, Yoichiro Mitsuishi, Fumiyuki Takahashi, Ken Tajima, Toshifumi Yae, Katsumi Miyahara, Daisuke Hayakawa, Wira Winardi, Hiroaki Ihara, Yoshika Koinuma et al. · 2019 · Bosnian Journal of Basic Medical Sciences
94. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells
    Yuji Sakuma, Yukiko Yamazaki, Yoshiyasu Nakamura, Mitsuyo Yoshihara, Shoichi Matsukuma, Shiro Koizume, Yohei Miyagi · 2012 · Biochemical and Biophysical Research Communications
95. Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening
    Siyuan Li, Xianqiang Sun, Hongli Zhao, Yun Tang, Minbo Lan · 2012 · Bioorganic & Medicinal Chemistry Letters
96. Dynamics of cancer recurrence
    Jasmine Foo, Kevin Leder · 2013 · The Annals of Applied Probability
97. Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis
    O’Farrell, Hannah, Harbourne, Bryant, Kurlawala, Zimple, Inoue, Yusuke, Nagelberg, Amy L., Martinez, Victor D., Lu, Daniel, Oh, Min Hee, Coe, Bradley P., Thu, Kelsie L. et al. · 2019 · Journal of Thoracic Oncology
98. Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy
    Yatao Wang, Peng-Cheng Yang, Jingyi Zhang, Jinfeng Sun · 2024 · Molecules
99. The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis
    Wei Wang, Xia‐Bo Shen, Wei Jia, Dabing Huang, Yong Wang, Yue-Yin Pan · 2019 · Therapeutic Advances in Medical Oncology
100. Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations
     Alessio Lodola, Donatella Callegari, Laura Scalvini, Silvia Rivara, Marco Mor · 2020 · Methods in molecular biology